Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature
Article in Cancer (April 2024)
The most recent citing publications are shown below. View all 47 publications that cite this research output on Dimensions.
Article in Cancer (April 2024)
Article in Frontiers in Oncology (April 2024)
Article in Leukemia & Lymphoma (February 2024)